Anavex Life Sciences Corp.

AVXL

Find Out if You Qualify for a Financial Reward by filling out the form below.

Anavex Life Sciences Corp. Form












Stock Fraud Law Center does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

On December 2, 2022, AVXL announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD). ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results. An analyst questioned the Company’s claim noting “there are several key factors that point us to believe the data is provocative, but not yet compelling, given the choice of statistical analyses and other trial design/conduct ‘complexifiers’.” Additionally, a biotech journalist commented on AVXL’s findings stating “[w]hat sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials…Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.”

Following this news, AVXL’s stock price fell by $2.47 per share, or approximately 20% to close at $9.58.

Further on January 3, 2024, AVXL announced that results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX®2-73 in pediatric patients with Rett syndrome failed to show statistical significance towards its primary endpoints. Biotech analysts commented that “the negative study outcome was never in doubt…Anavex is a serial dissembler of clinical trial results.”

Following this news, AVXL’s stock price fell by $3.26 per share, or approximately 35%.

Active Cases

Ticker SymbolCompany NameJoin DeadlineJoin
ASRTAssertio Holdings, Inc.March 05, 2024Join
DADADada Nexus LimitedMarch 11, 2024Join
BNTXBioNTech SEMarch 12, 2024Join
MBLYMobileye Global Inc.March 18, 2024Join
BIVIBioVie Inc.March 19, 2024Join
ALVRAlloVir, Inc.March 19, 2024Join
BTIBritish American Tobacco p.l.c.March 25, 2024Join
EVVTYEvolution AB (publ)March 25, 2024Join
ADMArcher-Daniels-Midland CompanyMarch 25, 2024Join
RILYB. Riley Financial, Inc.March 25, 2024Join
CARTMaplebear Inc. d/b/a InstacartMarch 25, 2024Join
EAFGrafTech International Ltd.March 25, 2024Join
SAVACassava Sciences, Inc.April 02, 2024Join
IRTCiRhythm Technologies, Inc.April 08, 2024Join
NYCBNew York Community Bancorp, Inc.April 08, 2024Join
HUTHut 8 Corp.April 08, 2024Join
XPOFXponential Fitness, Inc.April 09, 2024Join
AMLXAmylyx Pharmaceuticals, Inc.April 09, 2024Join
INMDInMode Ltd.April 15, 2024Join
AMPLAmplitude, Inc.April 15, 2024Join
NOVASunnova Energy International Inc.April 16, 2024Join
INODInnodata Inc.April 22, 2024Join
DKSDICK's Sporting Goods, Inc.April 22, 2024Join
FOXFFox Factory Holding Corp.April 22, 2024Join
LTRXLantronix, Inc.April 23, 2024Join
PANWPalo Alto Networks Inc.April 26, 2024Join
KINDNextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. IIApril 29, 2024Join
PLCEThe Children's Place, Inc.April 29, 2024Join
SNOWSnowflake Inc.April 29, 2024Join